Edwards Lifesciences jumps as CMS posts proposed TAVR coverage update

Edwards Lifesciences (EW) is up 3.4% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely catalyst is a U.S. reimbursement readthrough: CMS posted a proposed decision memo tied to its National Coverage Analysis for transcatheter aortic valve replacement (TAVR). Investors often treat steps in the TAVR coverage process as meaningful for procedure volumes and hospital adoption, which can flow through to Edwards’ structural heart sales.

Details:

CMS posted a proposed decision memorandum on June 15, 2026 as part of its National Coverage Analysis for TAVR (CAG-00430R2).

The proposed memo is part of an ongoing review process CMS initiated in December 2025, with subsequent milestones still ahead before a final determination.

TAVR is a core Edwards market, so any perceived shift toward broader or clearer coverage expectations can be interpreted as supportive for long-term demand.

This move could also reflect a relief rally as a widely watched, date-specific catalyst (the proposed memo) arrived without an unexpectedly negative surprise.

Sources:

Centers for Medicare & Medicaid Services, Investing.com, MassDevice

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$EW Insider Trading Activity

$EW insiders have traded $EW stock on the open market 24 times in the past 6 months. Of those trades, 0 have been purchases and 24 have been sales.

Here’s a breakdown of recent trading of $EW stock by insiders over the last 6 months:

DONALD E JR BOBO (CVP,Strategy/Corp Development) has made 0 purchases and 9 sales selling 110,473 shares for an estimated $9,248,862.
SCOTT B. ULLEM (CVP, Chief Financial Officer) has made 0 purchases and 4 sales selling 26,000 shares for an estimated $2,144,440.
BERNARD J ZOVIGHIAN (CEO) has made 0 purchases and 2 sales selling 22,430 shares for an estimated $1,719,741.
DANIEL J. LIPPIS (CVP, TAVR) has made 0 purchases and 7 sales selling 5,715 shares for an estimated $477,326.
DAVEEN CHOPRA (CVP, TMTT & Surgical) sold 1,500 shares for an estimated $126,905
ANDREW M. DAHL (SVP, Corporate Controller) sold 567 shares for an estimated $48,852

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$EW Hedge Fund Activity

We have seen 560 institutional investors add shares of $EW stock to their portfolio, and 636 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

DZ BANK AG DEUTSCHE ZENTRAL GENOSSENSCHAFTS BANK, FRANKFURT AM MAIN added 5,079,892 shares (+65.7%) to their portfolio in Q1 2026, for an estimated $406,797,751
NINETY ONE UK LTD added 4,661,197 shares (+60.3%) to their portfolio in Q1 2026, for an estimated $373,268,655
MILLENNIUM MANAGEMENT LLC removed 4,284,117 shares (-70.5%) from their portfolio in Q1 2026, for an estimated $343,072,089
ARTISAN PARTNERS LIMITED PARTNERSHIP added 4,034,429 shares (+345.8%) to their portfolio in Q1 2026, for an estimated $323,077,074
MARSHALL WACE, LLP removed 3,929,250 shares (-66.3%) from their portfolio in Q1 2026, for an estimated $314,654,340
BANK OF AMERICA CORP /DE/ added 2,212,208 shares (+132.4%) to their portfolio in Q1 2026, for an estimated $177,153,616
FMR LLC removed 2,078,777 shares (-12.5%) from their portfolio in Q1 2026, for an estimated $166,468,462

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$EW Government Contracts

We have seen $28,738,465 of award payments to $EW over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

EXPRESS REPORT: HEART VALVES: $295,500
TRANSCATHETER HEART VALVE REPLACEMENT SYSTEMS: $238,000
HEART VALVE: $238,000

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.

$EW Analyst Ratings

Wall Street analysts have issued reports on $EW in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

BTIG issued a "Buy" rating on 02/11/2026
Piper Sandler issued a "Overweight" rating on 01/20/2026
Stifel issued a "Buy" rating on 01/20/2026
Barclays issued a "Overweight" rating on 01/12/2026
TD Cowen issued a "Buy" rating on 01/09/2026

To track analyst ratings and price targets for $EW, check out Quiver Quantitative's $EW forecast page.

$EW Price Targets

Multiple analysts have issued price targets for $EW recently. We have seen 14 analysts offer price targets for $EW in the last 6 months, with a median target of $97.5.

Here are some recent targets:

Shagun Singh from RBC Capital set a target price of $100.0 on 06/16/2026
Joshua Jennings from TD Cowen set a target price of $104.0 on 06/02/2026
Matt Miksic from Barclays set a target price of $110.0 on 04/27/2026
Vijay Kumar from Evercore ISI Group set a target price of $93.0 on 04/24/2026
William Plovanic from Canaccord Genuity set a target price of $85.0 on 04/24/2026
Richard Newitter from Truist Securities set a target price of $90.0 on 04/24/2026
David Rescott from Baird set a target price of $87.0 on 04/24/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.